

OPAB Board Member Priorities August 2022-Feb 2025
Board Discussion Summary
August 4th, 2022
Angela Carter scribe

- **Ch 333 Rules review and revision**
 - Reassessment of synthetic Psilocybin products
 - Species and substrate reassessment

OPAB Strategic Plan Development for Safety, Affordability, and Accessibility

- **Initial Design and Planning Phase:**
 - Define Safety, Affordability and Accessibility
 - Develop quantitative metrics for assessment of the 3 requirements
 - Determine timeline, process, and dates for information submission to OHA to reach goal
 - Strategic plan development facilitator? (Angie will follow up)
 - Review of other strategic plans (cannabis) for templating and direction
- **Policy and Procedure Development Phase**
 - Design Methods to assure equitable access in location and transportation to service centers
 - Develop Mechanism to collect and analyze client-level data and integrate learning into OPAB and OHA work
 - Question of whether to Outsource data collection to a non-governmental independent agency that may garner funding for the development and implementation of data collection?
 - Academic medical center?
 - private research institutes?
 - OHA provide RFP for data collection and create MOU with stipulation to avoid financial COI?
 - Develop mechanism to solicit feedback and information from providers, manufacturers, and service centers
 - Board to Board agreements for dual-licensed providers (Psilocybin services has reached out to establish relationships)
 - Provider guidelines for dual-licensed providers
 - Insurance coverage for providers, service centers, and manufacturers
 - Definition and structure of Economic/Marketplace practices
 - Development of an evaluation plan for the training programs based on client outcomes, accessibility and affordability
 - Assuring Tribal access to services with ongoing consultation
- **Ongoing Federal Law Review**
 - Define parameters of laws and regulations to review and integrate
 - FDA policy, FTC, Agricultural regs, Education, correlation to cannabis field laws, Center for Medicare and Medicaid Services, DEA and prescriber concerns
 - How FDA potential future approval of Psilocybin and analogues may impact Oregon Psilocybin Services

OPAB Board Member Priorities August 2022-Feb 2025
Board Discussion Summary
August 4th, 2022
Angela Carter scribe

- **Meeting with US Attorney's office to discuss federal enforcement policies (after 2 years)**
 - Provide a robust regulatory scheme prior to approaching
 - Provide programmatic results and data collected to demonstrate programmatic safety and efficacy
 - Consider lessons learned on COLE Memo
 - Consider Ogden memo from 2009
 - Strategize on approach methods and relationship development
- **Ongoing recommendations to OHA for statutory changes**
 - Psilocybin Research licensure considerations around market level products as well as synthetics
 - Provider protections for dual-licensed providers
- **Research subcommittee review of literature and data presentations**
- **Equity Subcommittee ongoing recommendations and implementation**
 - Indigenous practitioner/Modalities subcommittee
 - Ensuring Tribal access to services

Next Steps for October 2022 OPAB Meeting:

Determine timeline, structure, definitions, and metrics that will guide the development of the strategic plan